Centro De Ingenieria Genetica Y Biotecnologia

Centro De Ingenicria Genetica Y Biotecnologia

Maribel Guerra Vallespi

Osvaldo Reyes Acosta

Boris Ernesto Acevedo Castro

Gerardo Enrique Guillen Nieto

Glay Chinea Santiago

Alexis Musacchio Lasa

Gerardo Enrique Guillén Nieto

Raimundo Ubieta Gómez

Hilda Elisa Garay Perez

Jeovanis Gil Valdés

Julio Raul Fernandez Masso

Hilda Elisa Garay Pérez

Isis Del Carmen Torrens Madrazo

Milaid Granadillo Rodriguez

Brizaida Maylin Oliva Argüelles

Isis Del Carmen Torréns Madrazo

Manuel De Jesús Araña Rosainz

Julio Raúl Fernández Massó

Manuel De Jesus Arana Rosianz

Manuel De Jesus Arana Rosainz

Isis Del Torrens Madrazo

This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.

Cancer therapy method

The present invention relates to use of a new cell penetrating peptides (CPP) and in particular to the region 32-51 of protein(LALF) and its analogous. This invention refers to compositions containing these peptides associated to biomolecules with therapeutics properties. This invention consist of compositions comprise the covalent fusion of biomolecules, between this human papillomavirus antigens (HPV) to these CPP for induce a potent immune cellular responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors. The referred compositions are applicable in the pharmaceutical industry as vaccine for therapeutic use in human.

Cell penetrating peptides and its use fused to biomolecules with therapeutic action

The present invention is related to the development of peptides derived from the sequence HYRIKPTFRRLKWKYKGKFW (SEQ ID NO.: 13), showing amino acid substitutions, these peptides unable to bind to the lipopolysaccharides and bearing anti-tumoral and immunomodulatory capacities. These peptides alone or in combination are useful to treat cancer, and also in synergy with conventional therapies.

Immunomodulatory and anti-tumour peptides

The present invention relates to analogues of peptides from lipopolysaccharide-binding protein (LBP) region whose primary sequence have been substituted at particular amino acid sites to obtain effective binding to, and neutralization of, lipopolysaccharide (LPS).

Analogues of lipopolysaccharide-binding protein (LBP)-derived peptides that efficiently neutralize lipopolysaccharides (LPS)

The present invention relates a novel immunological effect of one peptide from Limulus anti-LPS factor protein. The immunological effect are, (1) Induce an antiviral state in both the Hep-2 and MDBK cell lines, (2) Supernatant from human mononuclear cells stimulated with peptide Limulus anti-LPS factor (LALF) is able to induce antiviral effect on Hep-2 cell line by mean of IFN-&ggr; (3) LALF peptide is able to modulate the immune response in vitro and in vivo. The present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune responses, without stimulating the production of certain biochemical mediators (e.g., TNF-&agr;) that can cause detrimental effects, such as fever and inflammation.

Immunological activity for a peptide of the limulus anti-LPS factor

The present invention relates a novel immunological effect of one peptide from Limulus anti-LPS factor protein. The immunological effect are, (1) induce an antiviral state in both the Hep-2 and MDBK cell lines, (2) Supernatant from human mononuclear cells stimulated with peptide Limulus anti-LPS factor (LALF) is able to induce antiviral effect on Hep-2 cell line by mean of IFN-&ggr; (3) LALF peptide is able to modulate the immune response in vitro and in vivo. The present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune responses, without stimulating the production of certain biochemical mediators (e.g., TNF-&agr;,) that can cause detrimental effects, such as fever and inflammation.

Growing community of inventors

Ciudad de la Habana, Cuba

Maribel Guerra Vallespi